Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results. by Carroll, PB et al.
I . 
t '. . 
l 
4. Baron S. Salicylate5 as hypoglycemic agents. Diabetes Can. 1982;5:6+71. 
5. Alvan G, &rgman U, Gustafsson LL High unbound fraction of salicylate in 
plasma during intoxication. Dr J Clin Phanrta<:ol. 1981;11:625-626. 
6. American Hospital Formulary Service. Drug Information: glyburide. 1993: 
1973-1978. 
7. Anderson RJ, Potts DE, Gabow PA, et al. Unrecognized adult salicylate in-
toxication. Ann Intern M<d. 1976;85:745-748. 
Iffect of '.croll.u. (FKS06, I. Dptrophlc 
Ipl ........ apl. Bull ........... 1 ••• tI 
.... II.I.IIIY ••• ulta 
P rogress has been made in understanding skin diseases such as epidermolysis bullosa (EB). 
Epidermolysis bullosa is characterized by 
abnormal skin fragility and the formation of blisters 
and erosions of the skin and mucous membranes in 
response to minor trauma. The disease manifests in 
infancy, and, by childhood, patients have cutaneous 
scarring and mucosal involvement that call be severe. 
Treatment is palliative. Tacrolimus (FK506) is a new 
immunosuppressive agent used in organ transplanta-
tion. This agent has a number of nonimmune effects, 
one of which is augmentation of cell regeneration and 
repair.l With the rationale of stimulating wound heal-
ing, we administered tacrolimus to a 5-year-old boy 
with dystrophic EB. There were no toxic effects, and 
scabs could form and affected areas heal since disease 
onset and treatment dramatically shortened the time 
to heal new lesions. 
Report of a Case. Our patient was normal at birth. 
Blistering began at 2 months; at 4 months, diagnostic 
biopsy specimens were obtained that showed an intact 
epidermis and strands of collagen separating from the 
dermis sub-lamina densa with sub-lamina densa cleav-
age. Findings from transmission electron microscopy 
were compatible and showed reduced anchoring fibrils 
in areas of blisters. Tests for anti-type VII collagen 
antibodies showed negative findings and immunofluo-
rescence mapping showed bullous pemphigoid anti-
gen; laminin and type IV collagen were normally 
expressed along the basement membrane zone. There 
was no family history of skin disease. The child was 
enrolled in the National EB Registry. University of Ala-
bama, Birmingham. as dystrophic EB. pt,Dbably domi-
nant, although a recessive or a spontaneous mutant 
dominant was pOSSible. As a result of EB. he had mul-
tiple wound infections and lost his toenails and finger-
nails. Diffuse scars and blistering lesions developed. 
Corneal erosions were noted on two occasions. Find-
ings from barium swallow and endoscopy were nega-
tive. The mouth lesions of EB resulted in poor weight 
gain. The child was treated for 2 years with dilantin 
without benefit. At baseline evaluation for tacrolimus. 
he wore mittens constantly and his whole body was 
being wrapped and treated with topical agents several 
times daily. Although he was developmentally normal, 
he was in a special-needs class because of EB and was 
severely inhibited in his ability to play with other chil-
dren. 
New skin lesions that occurred on tacrolimus (Ff( 506) treatment. The 
photographs illustrate the character of fIfIW lesions that continued to occur 
while receMng taero/imus. New lesions that developed are shown on the 
IefI and the healing that took place is indicated by the foUow-up picture of 
the same area on the right. Some lesions had never healed si/1C6 onset of 
dis8as8, and, at baseline, new lesions took more than 30 days to heal and 
Mill characteriZed by blistering. At 2 weeks (top), new lesions were stilI 
characteriZed by blisters (upper left panel). Blisters no longer formed after 
2 months (center) of therapy, scabs formed for the first time (bottom), 
and the time to heal new lesions slowty improved to 10 days at 3 months, 
7 days at 6 months, and 3 to 5 days at 9 months, and is cu"entJy 3 to 5 
days. 
After informed consent, tacrolimus therapy com-
menced (0.7 mg orally twice a day). The child was 
photographed serially, and the time to heal new 
lesions was determined. The activity of his disease was 
followed by counting the total number of skin lesions 
and the percentage of skin involved using a modifica-
tion of the PASI (Psoriasis Activity and Severity Index) 
score used in psoriasis patients. The total score before 
treatment was 184.7, at which time he had 29 lesions 
ranging in size up to a maximum diameter of 83 mm. 
covering more than 30% of his body. While receiving 
tacrolimus, the total score as well as the percentage of 
body involved have decreased to 84.4 and 15%. 
respectively, although there have been fluctuations 
due to major skin traumas. The .... re shows the 
healing of lesions while receiving tacrolimus. At 2 
weeks, blistering lesions still occurred (upper panels). 
After receiving tacrolimus for 2 months, the character-
istics of the lesions changed to dry abrasions rather 
than blisters (middle and lower panels). Scabs formed 
and new and old lesions healed. The time to heal new 
lesions was greater than 30 days at baseline. decreased 
to 10 days at 3 months, 7 days at 6 months. 3 to 5 
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days at 9 months, and is currently 3 to 5 days. New 
lesions continue to form in areas of trauma. Finger-
nails and toenails have regrown. 
The child has no mouth lesions and has gained 3.6 
kg during treatment. Tacrolimus levels have ranged from 
0.2 to 0.5 nglmL with no evidence of toxic effects. The 
year before tacrolimus therapy began, the child had two 
infections treated with antibiotics and had an 18.4% ab-
sentee rate from school. During 18 months of treat-
ment, he had no infections and had an absentee rate from 
school of 3.76%. He no longer requires constant wrap-
ping and has been enrolled in a class for nonnal stu-
dents. 
Comment. Epidermolysis bullosa is classified into 
subtypes that are delineated based on the clinical fea-
tures, pathologic findings, immune markers, and the 
mode of inheritance. In patients with dystrophiC EB, 
the number of anchoring fibrils in the upper dermis 
are reduced and blisters occur below the lamina 
densa. 2 Increased collagenase activity in fibroblasts 
isolated from the skin of patients with dystrophic EB 
has been described and may be a useful probe.3 Tacro-
limus induces TGF-beta gene expression· that might 
increase syntheSiS of type VII collagen followed by ref-
ormation of anchoring fibrils.5 This might be one 
mechanism to investigate t'he possible effects of tacro-
limus on wound healing in EB. This disease has peri-
odic fluctuations related to skin trauma, and, with a 
case report, conclusions cannot be definitive; however, 
this child's response to tacrolimus therapy provides an 
impetus for further studies of its use in EB. 
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